A proposal to certify a national class action suit of users claiming to being harmed by Yaz or Yasmin had been denied by a federal judge. The ruling was issued by the same federal judge who was managing the multi-district litigation (MDL) over the birth control . The MDL encompasses large numbers of individual cases that make similar allegations.  In the Yaz MDL, the individual cases include accusations of negligence, strict product liability, breach of express warranty, breach of implied warranty, fraudulent misrepresentation, fraudulent concealment, negligent misrepresentation, medical monitoring, and fraud and deceit against Bayer Pharmaceutical regarding side effects. All the individual plaintiffs making these claims have already suffered from adverse effects of Yaz or Yasmin.  The class action lawsuit had been filed by other lawyers on behalf of women who might have taken Yaz or Yasmin, but had not yet suffered an identifiable injury.  Such class action lawsuits typically ask the manufacturer of the drug to establish funds to pay for medical monitoring, so past users of the drug can detect the side effects quickly.  Such class action suits are denied if the judge feels that the group to be monitored is too diverse to have a manageable monitoring plan.

Bayer Pharmaceuticals, the manufacturer of Yaz and Yasmin first received approval for this type of contraceptive drug from the FDA in 2001. Since, then it has being used to prevent pregnancy.  Later, Yaz was also approved by the FDA for treatment of premenstrual dysphoric disorder (PMDD) and acne.

There are numerous lawsuits filed against Bayer related to of Yaz and Yasmin. More than 1500 such lawsuits are related to gallbladder diseases. These lawsuits have been filed in both state and federal courts.

Yaz and Yasmin are oral contraceptive pills containing synthetic progestin drospirenone and ethinyl estradiol. Drospirenone when combined with ethinyl estradiol could develop gallbladder diseases like cholecystitis (inflammation of the gallbladder) and cholelithiasis (gallstones). Drospirenone is also considered responsible for formation of blood clots in the patient, which can lead to pulmonary embolism and deep vein thromboembolism (also known as deep vein thrombosis). If these clots travel to heart or block blood flow fully to and from the heart, it can cause heart attack and even death in some cases.  When the clots are carried into the brain, a stroke can occur.

Previous ArticleYaz-Yasmin: Medifacts and Uses Next ArticleJury Verdict is awaited as first blood clot trial in YAZ-Yasmin MDL moved to January 2012
Verdicts and Settlements
Newsletter
Contact Us

Subscribe Now!

[contact-form-7 404 "Not Found"]

Follow Us!

Unsafe Drugs has numerous resources on drug side effects,nutritional supplements, vitamins, and health products.

Site best viewed in Google Chrome, Firefox, Opera, Safari, IE browsers